275 filings
Page 3 of 14
8-K
krg04vgqlrhg06308fo
2 Oct 23
Regulation FD Disclosure
8:40am
8-K
uoumkfo2e6vxl0
21 Sep 23
Regulation FD Disclosure
8:50am
8-K
x4gg3y0kyt
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
dvteg s0xea8c
14 Sep 23
Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
8:35am
8-K/A
vheyke
23 Aug 23
Regulation FD Disclosure
4:07pm
8-K
rg0c01by75q9nxhz
21 Aug 23
Amendments to Articles of Incorporation or Bylaws
5:17pm
8-K
ywv6icel08
21 Aug 23
Regulation FD Disclosure
7:30am
8-K
cd7 zf54l
11 Aug 23
Moleculin Reports Second Quarter 2023 Financial Results
7:00am
8-K
yxvd6i do60t5
10 Aug 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:05pm
8-K
izcq1wzsi t89og
7 Aug 23
Regulation FD Disclosure
8:40am
8-K
eahtf
3 Aug 23
Regulation FD Disclosure
8:45am
8-K
jdrom6ai22lga31w44
13 Jul 23
Regulation FD Disclosure
12:00am
8-K/A
k7qdita9b7u
16 Jun 23
Submission of Matters to a Vote of Security Holders
4:16pm
8-K
kcsnlpi
13 Jun 23
Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
8:35am
8-K
wnjq e1vp9kon
26 May 23
Submission of Matters to a Vote of Security Holders
7:37am
8-K
b2ejqast6o
12 May 23
Regulation FD Disclosure
5:05pm
8-K
q1d9yqio rqsudx1h7
11 May 23
Moleculin Reports First Quarter 2023 Financial Results
7:05am
8-K
mltnewr3 fu33it33w
10 May 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:07pm
8-K
byif59v5 n1
5 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
fp53qyw2d
4 May 23
Regulation FD Disclosure
8:40am